TERN-501 explained

Legal Status:	Investigational
Pubchem:	146402726
Chembl:	4782668
Iupac Name:	N-[3,5-dichloro-4-(1-methyl-6-oxo-5-propan-2-ylpyridazin-3-yl)oxyphenyl]-5-oxo-4H-1,2,4-oxadiazole-3-carboxamide
C:	17
H:	15
Cl:	2
N:	5
O:	5
Stdinchi:	1S/C17H15Cl2N5O5/c1-7(2)9-6-12(22-24(3)16(9)26)28-13-10(18)4-8(5-11(13)19)20-15(25)14-21-17(27)29-23-14/h4-7H,1-3H3,(H,20,25)(H,21,23,27)
Stdinchikey:	WFIWVDVCNWOMQV-UHFFFAOYSA-N
Smiles:	CC(C)C1=CC(=NN(C1=O)C)OC2=C(C=C(C=C2Cl)NC(=O)C3=NOC(=O)N3)Cl

TERN-501 is a selective thyromimetic drug that is being developed for the treatment of non-alcoholic fatty liver disease.^{[1] [2]}

Notes and References

1. Finan . Brian . Parlee . Sebastian D. . Yang . Bin . Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH . Molecular Metabolism . April 2021 . 46 . 101153 . 10.1016/j.molmet.2020.101153. 33359400 . 8085542 . free .
2. Karim . Gres . Bansal . Meena B . Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis . TouchREVIEWS in Endocrinology . 2023 . 19 . 1 . 60–70 . 10.17925/EE.2023.19.1.60 . 37313239 . 10258622 . 2752-5457.